Biotech Values

[DewDiligence]

MNTA
This stock has given back about a third of the huge pop it experienced when SNY’s Lovenox patent was thrown into question in June (#msg-6701212). Here's a blurb on today’s CC I picked up from SI (emphasis added):

>>
MNTA Momenta Pharma: (19.38 -1.61) -Update-

Rodman & Renshaw notes that after MNTA reported Q3 results this morning, and says they do not expect to receive much information from MNTA on the FDA proceedings and so it may be difficult going forward to know how the ANDA is progressing.

The firm says that it appears the degree of hedging about the approvability of other products and the FDA process for MNTA's ANDA has increased, which can be received negatively by investors. They continue to believe that MNTA's technology will uniquely allow it to meet the FDA's guidelines for chemical and biologic equivalence, but say mgmt commented that a deal this year is unlikely for either M-dalteparin or the glycoprotein complex mixture characterization programs. They are having a hard time understanding why MNTA is no longer filing an ANDA for their M-dalterparin given the substantial capital the co now has on hand.
<<